^
    Back
    Association details:
    Biomarker:HR negative + PD-L1 expression
    Cancer:HER2 Negative Breast Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    03/29/2021
    Excerpt:
    Invasive Breast Cancer: HR-negative/HER2-negative...Preferred first-line therapy...Pembrolizumab + chemotherapy (albumin-bound paclitaxel, paclitaxel or gemicitabine and carboplatin)
    Secondary therapy:
    GemCarbo; albumin-bound paclitaxel; paclitaxel
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    HER2 Negative Breast Cancer: Invasive Breast Cancer…ADDITIONAL TARGETED THERAPIES AND ASSOCIATED BIOMARKER TESTING FOR RECURRENT OR STAGE IV (m1) DISEASE…HR-negative/HER2-negative…PD-L1 expression...pembrolizumab+chemotherapy (albumin-bound paclitaxel, paclitaxel or gemcitabine and carboplatin)...
    Secondary therapy:
    paclitaxel; albumin-bound paclitaxel; carboplatin; gemcitabine